CN106727586A - A kind of new opplication of Artesunate - Google Patents
A kind of new opplication of Artesunate Download PDFInfo
- Publication number
- CN106727586A CN106727586A CN201611106935.3A CN201611106935A CN106727586A CN 106727586 A CN106727586 A CN 106727586A CN 201611106935 A CN201611106935 A CN 201611106935A CN 106727586 A CN106727586 A CN 106727586A
- Authority
- CN
- China
- Prior art keywords
- cell
- cells
- art
- akt
- artesunate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960004991 artesunate Drugs 0.000 title claims abstract description 30
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 title claims abstract description 30
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims abstract description 25
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims abstract description 21
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229940120982 tarceva Drugs 0.000 claims abstract description 21
- 230000002441 reversible effect Effects 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 38
- 229940079593 drug Drugs 0.000 claims description 22
- 239000000890 drug combination Substances 0.000 abstract description 11
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 9
- 201000005202 lung cancer Diseases 0.000 abstract description 9
- 208000020816 lung neoplasm Diseases 0.000 abstract description 9
- 239000003795 chemical substances by application Substances 0.000 abstract description 8
- 238000011275 oncology therapy Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 143
- 230000014509 gene expression Effects 0.000 description 42
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 39
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 description 35
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 32
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 32
- 238000011580 nude mouse model Methods 0.000 description 29
- 241000699660 Mus musculus Species 0.000 description 28
- 239000000243 solution Substances 0.000 description 28
- 206010028980 Neoplasm Diseases 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 16
- 102000038030 PI3Ks Human genes 0.000 description 15
- 108091007960 PI3Ks Proteins 0.000 description 15
- 230000008859 change Effects 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 238000011282 treatment Methods 0.000 description 14
- 238000001262 western blot Methods 0.000 description 14
- 230000004913 activation Effects 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 108090000397 Caspase 3 Proteins 0.000 description 11
- 102100029855 Caspase-3 Human genes 0.000 description 11
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 11
- 201000005249 lung adenocarcinoma Diseases 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 101000911513 Homo sapiens Uncharacterized protein FAM215A Proteins 0.000 description 10
- 102100026728 Uncharacterized protein FAM215A Human genes 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 235000015097 nutrients Nutrition 0.000 description 10
- 230000026731 phosphorylation Effects 0.000 description 10
- 238000006366 phosphorylation reaction Methods 0.000 description 10
- 229940121647 egfr inhibitor Drugs 0.000 description 9
- 230000003834 intracellular effect Effects 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 230000006907 apoptotic process Effects 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 8
- -1 boils 5min Substances 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 230000007783 downstream signaling Effects 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000007619 statistical method Methods 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000004042 decolorization Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000006059 cover glass Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000012737 fresh medium Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000011242 molecular targeted therapy Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000001405 Artemisia annua Nutrition 0.000 description 1
- 240000000011 Artemisia annua Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100026550 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 102100032218 Cytokine-inducible SH2-containing protein Human genes 0.000 description 1
- 101710132484 Cytokine-inducible SH2-containing protein Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101150022345 GAS6 gene Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101100193693 Kirsten murine sarcoma virus K-RAS gene Proteins 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 102100040421 Treacle protein Human genes 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 229960004191 artemisinin Drugs 0.000 description 1
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 1
- 229930101531 artemisinin Natural products 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 201000003373 familial cold autoinflammatory syndrome 3 Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003694 hair properties Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000000032 total current spectroscopy Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention provides a kind of new opplication of Artesunate, and Artesunate is used to reverse adenocarcinoma of lung Tarceva resistance, or Artesunate and Tarceva drug combination.Resistance is eventually produced to solve existing molecular targeted agents, its problem clinically applied is limited.The invention belongs to lung cancer therapy field.
Description
Technical field
Adenocarcinoma of lung Tarceva resistance is reversed the present invention relates to one kind, belongs to lung cancer therapy field.
Background technology
Lung cancer is to cause cancer-related death chief reason, and the treatment for appearing as lung cancer of molecular targeted therapy brings
New hope, it has clear and definite action site, and adverse reaction is small, determined curative effect.The shortcoming of molecular targeted agents is it
It is expensive, can not fully erased focus, and eventually produce resistance, this point limits its application clinically..
The content of the invention
It is an object of the invention to:A kind of new opplication of Artesunate is provided, it is final to solve existing molecular targeted agents
Resistance can be produced, its problem clinically applied is limited.
To solve the above problems, intend using the new opplication of such a Artesunate, Artesunate is used to reverse adenocarcinoma of lung
Tarceva resistance, further, Artesunate and Tarceva drug combination.
Artesunate is used for the reverse research method of adenocarcinoma of lung Tarceva resistance:
ART is studied the external anti-tumor activity of human lung adenocarcinoma PC9 cells:Culture PC9 cell lines, add various concentrations
ART, with cell Counting Kit-8 (cck-8) detect PC9 cells proliferation rate, Real-time RT-PCR and
The expression of western-blot detection EGFR, IGF1R, AXL and Akt mRNA, albumen and apoptosis-related protein;
The culture of Tarceva secondary resistance cell line and the detection of drug resistance:The increasing of PC9/ER is detected with cck-8 methods
Grow rate, calculate resistance multiple, Real-time RT-PCR and western-blot detection EGFR, IGF1R, AXL, Akt mRNA and
The expression of albumen;
Experiment in vitro checking ART reverses effect and the mechanism of adenocarcinoma of lung ER resistances:Added in PC9/ER cell lines different
ART, ER or drug combination of concentration, and with LY294002 as positive control, proliferation rate, Real-time RT- are surveyed with cck-8 methods
The expression of PCR and western-blot detection EGFR, IGF1R, AXL and Akt m RNA and albumen;
By transplanted tumor in nude mice experiment in vivo verify ART reverse adenocarcinoma of lung ER resistances effect and mechanism, Tarceva after
Hair property medicine-resistant cell line abbreviation PC9/ER, Tarceva abbreviation ER, Artesunate abbreviation ART.
Compared with prior art, Artesunate of the present invention can effectively reverse adenocarcinoma of lung Tarceva resistance, coordinate
Lung cancer for prognosis can effectively be improved after Tarceva, solve the problems, such as that molecular targeted agents can produce resistance well, entered
The application clinically of one step propulsion molecular targeted agents.
Brief description of the drawings
Cell quantity and morphologic change after various concentrations Artesunate treatment PC9 cells under Fig. 1 light microscopes
(x200), wherein:
A:0.1%DMSO control groups; B:25 μm of ol/L groups of Artesunate
C:Artesunate 50mol/L groups; D:Artesunate 100mol/L groups;
Inhibited proliferation of Fig. 2 Artesunates to PC9 cells;
After Fig. 3 Artesunates treatment 48h in cell EGFR, IGF1R, AXL and Akt mRNA relative expression, note:*p<
0.05vs control**p<0.01vs control;
After Fig. 4 Artesunates treatment 48h in PC9 cells EGFR, IGF1R, AXL and Akt and its phosphorylation expression;
After Fig. 5 Artesunates treatment 48h in PC9 cells apoptosis-related protein expression;
Fig. 6 Artesunates are to PC9 cells and the inhibited proliferation of PC9/ER cells;
Fig. 7 different experiments groups act on the protein expression and phosphorylation level situation of change of IGF1R and AXL after PC9/ER cells;
Fig. 8 different experiments groups act on the protein expression and phosphorylation level situation of change of Akt after PC9/ER cells;
Fig. 9 different experiments groups act on the expression of apoptosis-related protein and phosphorylation level situation of change after PC9/ER cells;
Figure 10 different experiments group nude mice body weight situations of change;
Figure 11 different experiments group nude mice tumor volume situations of change, note:*p<0.05vs Con groups n=5.
Specific embodiment
To make the object, technical solutions and advantages of the present invention clearer, invention will be described in further detail below.
Experimental example 1:
Artesunate is studied the external anti-tumor activity of human lung adenocarcinoma PC9 cells
1 materials and methods
1.1 major experimental materials
1.1.1 cell line
Human lung adenocarcinoma PC9 cells are given by the entire PLA of new bridge hospital of Third Military Medical University institute of oncology professor Chen Zhengtang.
1.1.2 main agents
1.1.3 main material equipment
1.2 experimental techniques
1.2.1 the recovery of cell, cultivate, pass on and freeze
The recovery of tumour cell and culture
The cryopreservation tube that will be equipped with human lung adenocarcinoma PC9 cell lines is taken out from liquid nitrogen container, and 37 DEG C -40 DEG C are put into rapidly equipped with warm water
Beaker in quickly rock, the cell liquid for freezing quickly is dissolved in 30s, cell is transferred in sterile centrifugation tube, add
RPMI-1640 nutrient solutions ((FBS) containing 10% hyclone) 5ml, cell suspension is softly blown and beaten into by cell, in centrifuge from
The heart (1000rpm is centrifuged 3-5min), sucks supernatant, the 5ml of RPMI-1640 nutrient solutions (containing 10%FBS) is added, by cell
Piping and druming is planted in 25ml blake bottles after mixing, and is placed in 37 DEG C, 5%CO2Cultivated in the cell incubation case of saturated humidity, incubated overnight
It is in adherent growth after visible cell is observed under inverted microscope, sucks supernatant, washed 2-3 times with PBS solution, adds
RPMI-1640 nutrient solutions (containing 10%FBS) 5ml.In observation of cell form under inverted microscope, liquid is changed in good time.
The passage of tumour cell
In observation of cell form under inverted microscope, see that cell is covered with left to the 80-90% of Tissue Culture Flask bottom of bottle volume
Can be passed on when right, it would be desirable to which the human lung adenocarcinoma PC9 cells of passage are placed in super-clean bench, outwell the old nutrient solution in blake bottle,
Washed 2-3 times with PBS solution, with the 0.25% trypsase 1-2ml vitellophags containing 0.025%EDTA, cover bottle cap rearmounted
In observation of cell under inverted microscope, a small amount of fresh medium containing 10%FBS is rapidly added when cell withdraws projection change bowlder,
The cell for having digested softly is blown and beaten repeatedly to disengage it from cultivating bottle wall, cell is transferred in a new centrifuge tube, in centrifuge
Centrifugation (1000rpm, 3-5min), at this moment can see that there is one layer of white precipitate centrifuge tube bottom, the cell being as collected into, carefully
Supernatant is abandoned in suction, is added a certain amount of fresh culture (the big bottles of 7-10ml/, 3-5ml/ bottles) containing 10%FBS and is made carefully
Born of the same parents' suspension, gently piping and druming is mixed, and is then dispensed into again in new blake bottle, is placed in 37 DEG C, 5%CO2The cell of saturated humidity is incubated
Educate culture in case.Fresh medium was changed after passage per 2-3 days, using exponential phase cell as experimental subjects.
Tumour cell freezes
Selection is in the human lung adenocarcinoma PC9 cells of exponential phase, is most better than and freezes previous evening and change liquid, then with containing
The 0.25% trypsase 1-2ml vitellophags of 0.025%EDTA, in being observed under inverted microscope, become when cell withdraws projection
Bowlder is rapidly added a small amount of fresh medium containing 10%FBS, the cell for having digested softly is blown and beaten repeatedly and disengages it from blake bottle
Wall, and cell suspension is dispersed into, then cell is transferred in new centrifuge tube, (1000rpm is centrifuged 3- for centrifugation in centrifuge
5min), at this moment can see that there is one layer of white precipitate centrifuge tube bottom, the cell being as collected into, careful suction abandons supernatant, then adds
Enter the DMEM high glucose mediums containing 10%DMSO and 30% hyclone, be transferred in 2ml cryopreservation tubes after mixing cell, according to -4
30min is placed in DEG C refrigerator, 2h is placed in -20 DEG C of refrigerators, after -80 DEG C of sequential processes of refrigerator overnight, in moving into liquid nitrogen container
It is long-term to preserve.
1.2.2 cell count
Cell counting count board and cover glass are wiped with 75% absolute ethyl alcohol, is dried standby.Cover glass is covered after drying
On the counting chamber of blood counting chamber.One bottle of human lung adenocarcinoma PC9 cell is taken, 0.25% tryptose containing 0.025%EDTA is added
Enzyme 1-2ml, is observed under inverted microscope, and a small amount of fresh cultured containing 10%FBS is rapidly added when cell withdraws projection change bowlder
Liquid, softly blows and beats the cell for having digested and disengages it from cultivating bottle wall, and be dispersed into single cell suspension repeatedly.Then will be single with pipette tips
Cell suspension suctions out a little (about 200 μ l), is added dropwise at cover glass edge, makes sky of the single cell suspension full of cover glass and tally
Between gap.In being examined under inverted microscope and calculate four TCSs of block plaid, the principle that the cell of line ball is followed
It is to disregard a lower and meter left side on meter to disregard the right side.Then calculated by formula:Cell number/ml:Four cell number sum/4 × 10 of big lattice4
× extension rate.Count 3 times respectively, average.
1.2.3 cck-8 detects inhibited proliferations of the ART to human lung adenocarcinoma PC9 cells
The PC9 cells of exponential phase are pressed into each hole 5 × 103The density of individual cell is seeded in 96 orifice plates, is per hole
100 μ l, put 37 DEG C, 5%CO2After cultivating 24h in incubator, ART is added its final concentration is respectively 0 μm of ol/L, 6.25 μm of ol/
L, 12.5 μm of ol/L, 25 μm of ol/L, 50 μm of ol/L, 100 μm of μ l of ol/L final volumes 150, and zeroing group, negative control are set
(0.1%DMSO), blank control group, each concentration repeat 3 holes.Respectively after culture 24h, 48h, 72h, careful suction abandons supernatant,
The RPMI-1640 fresh cultures without FBS are added per hole, then adds 10 μ l cck8 solution (to try not to produce gas per hole
Bubble, in order to avoid the reading of influence OD values), 96 orifice plates are placed in 37 DEG C, 5%CO2Continue to be incubated 1-4h (preferably consistent) in incubator
Afterwards, with absorbance (OD) value at ELIASA Detection wavelength 490nm.
Cell proliferation rate (%)=[A (intervention)-A (blank)]/[A (feminine gender)-A (blank)] × 100
A (intervention):The absorbance of cell+nutrient solution+cck-8 solution+drug solution;
A (blank):The absorbance of nutrient solution+cck-8 solution;
A (feminine gender):The absorbance of cell+nutrient solution+cck-8 solution;
Cell inhibitory rate (%)=1- cell proliferation rates (%)
1.2.4 Real-time RT-PCR detect the expression of intracellular mRNA
The extraction of RNA
Growth selection is in good condition, exponential phase PC9 cells, by 5 × 105It is individual that cell/bottle is inoculated in 75ml is thin
In born of the same parents' blake bottle.Drug-treated is separately added into after 24h, experimental group is ART (25 μM, 100 μM), and 0.1%DMSO solution is in addition
Control group.After drug-treated, 37 DEG C, 5%CO are placed in2, 48h is cultivated in the cell incubation case of saturated humidity.By in blake bottle
Old nutrient solution is blotted only, then is cleaned 2-3 times with the PBS solution of precooling, finally blots the PBS solution in net Tissue Culture Flask.
1ml Trizol are added in every bottle of cell, nothing is transferred to after standing about 3-5min on ice, fully being blown and beaten with suction pipe
In EP pipes (1.5ml) of enzyme.
The chloroform of 1/5 volume is subsequently adding, mixing of turning upside down places 10min after 37 DEG C.In low-temperature and high-speed centrifuge
Middle centrifugation (4 DEG C, 12000g, 15min), carefully takes out EP pipes from centrifuge, and liquid is divided into three layers (upper strata is after centrifugation
RNA, middle level is DNA and bottom is protein), it is careful to draw upper strata to another new EP pipes.
Isometric isopropanol is added, turn upside down mixing EP liquid in pipe, 37 DEG C of placement 10min.In low-temperature and high-speed from
(4 DEG C, 12000g, 10min) are centrifuged in scheming, careful suction abandons supernatant.
Lentamente 75% ethanol 1mL is added along tube wall.In (4 DEG C, 1000g, 5min) are centrifuged on centrifuge, careful suction is abandoned
Clear liquid, places empty dry by the sediment in EP pipes.
Often pipe adds 20 μ L DEPC solution (depending on precipitation capacity), after being completely dissolved, -80 DEG C of preservations.Then with ultraviolet point
OD value of the light photometric determination total serum IgE at 260nm and 280nm, calculates concentration and purity.
Reverse transcription
Carried out using Dalian TaKaRa reverse transcription reagent box, reaction condition is as follows:
Being placed in after aforesaid liquid is mixed on Bio Rad-PCR reaction instrument carries out reverse transcription reaction (37 DEG C of 30min), then
Inactivation reverse transcriptase (85 DEG C of 5s).
Real-time fluorescence quantitative PCR
Real-time quantitative PCR detection is carried out using Bio-Rad systems
Reaction system:The μ L of cumulative volume 20, set three multiple holes.
Amplification curve condition:95 DEG C of 30 seconds (predegeneration) → 95 DEG C (40 circulations) in 5 seconds → 60 DEG C 40 seconds (amplified reactions).
Solubility curve condition:72℃.
MRNA primers
Table 1 is used for the primer of Real-time RT-PCR
Interpretation of result processes (relative quantification method):
A.Ct average=(Ct1+Ct2+Ct3)/3 (repeating pipe);
B.dCt=Ct average- medians;
C. expression=2 ∧ (- dCt) of gene;
D. the expression of the expression/reference gene of relative quantification=genes of interest
1.2.5 Western blot detect the expression of intracellular protein
Take the people's lung after experimental group (final concentration of 25 μM, 100 μM of ART) and control group (0.1%DMSO solution) treatment 48h
Old nutrient solution is abandoned in gland cancer PC9 cells, suction, is cleaned 2-3 times with the PBS solution of precooling, adds RIPA lysates (to be mixed with protease
Inhibitor and inhibitors of phosphatases) the abundant cell lysis of 1ml, in 30min is stood on ice, cell is gently scraped off culture bottle wall,
It is transferred in EP pipes, in centrifugation (4 DEG C, 12000g, 20min) on low-temperature and high-speed centrifuge.
A small amount of supernatant is taken, BCA methods determine protein concentration.Albumen is adjusted to same concentration, by 1:4 ratios addition 5 × on
Sample buffer solution, boils 5min, and sample is carefully added into the sample well of polyacrylamide gel after after thoroughly cooling.
Electrophoresis:Polyacrylamide gel electrophoresis (polyacrlamine gel electrophoresis, PAGE) is carried out to turn
Film (wet turn):Transferring film is carried out using the wet systems that transfer from one department to another of Bio-Rad, through the transfer of 150V (time of transferring film is determined by molecular size range)
Afterwards;Washed with TBS 3 times, every time 10 minutes.
Closing:TBS containing 5% skimmed milk power is closed 1 hour.
Primary antibody is incubated:After skimmed milk power closing, cleaned with TBST 3 times, 10 minutes/time, add primary antibody, -4 DEG C of refrigerators are abundant
Overnight incubation.
Secondary antibody is incubated:TBST rinse 3 times, 10 minutes every time, add horseradish peroxidase-labeled specific secondary antibody (with
1:5000 dilution proportions) in, it is positioned on shaking table, normal temperature is incubated 1 hour.
TBST is washed 3 times, every time 10 minutes.
Detection:Detected with ECL chemoluminescence methods, then carried out gel imaging instrument scanning.
1.3 statistical methods
Every group of experiment in triplicate, statistical analysis is carried out with SPSS20.0 statistical softwares to obtained experimental data, is owned
Data are represented with mean ± standard deviation (mean ± SD), using one-way analysis of variance analysis group difference.P<0.05 thinks
It is variant, P<0.01 thinks there is significant difference.
2 results
2.1 ART are on human lung adenocarcinoma PC9 cell quantities and morphologic influence
PC9 cells are acted on the ART of final concentration of 25 μm of ol/L, 50 μm of ol/L and 100 μm of ol/L, in optics after 48h
Basis of microscopic observation, is compared with control group (0.1%DMSO), and the cell quantity of each medication group is significantly reduced, and cellular morphology is by short
Fusiformis gradually becomes irregular shape or triangle, and with the increase of dosage, quantity is reduced must be become apparent from.(see Fig. 1)
2.2 influence using cck-8 methods detection ART to PC9 ability of cell proliferation
PC9 is acted on final concentration of 6.25 μm of ol/L, 12.5 μm of ol/L, 25 μm of ol/L, 50 μm of ol/L and 100 μm of ol/L
Cell, determines the OD values of 490nm wavelength after 24h, 48h and 72h, as a result show, the ART of various concentrations size is to PC9 cells
Multiplication capacity has an impact, and has dose dependent, and the IC50 for being computed 48h is 32.14 ± 4.69 μm of ol/L.(be shown in Table 2 and
Fig. 2)
The sweet wormwood of table 2Amber ester pairPC9 cell inhibitory effect effects
Group difference*P < 0.05:Group difference #p < 0.05
Influences of 2.3 ART to EGFR, IGF1R, AXL and AKT mRNA expression in adenocarcinoma of lung PC9 cells
Experimental group (ART25 μm of ol/L and 100 μm of ol/L) and control group (0.1%DMSO solution) effect 48h are collected respectively
PC9 cells afterwards, extract row Real-time RT-PCR detections after total serum IgE, by Bio-Rad systems obtain intracellular EGFR,
The Relative copy number of IGF1R, AXL and Akt gene.Compare with control group, PC9 intracellular EGFR mRNA after experimental group treatment
Expression quantity increase compared with control group, and the expression quantity of IGF1R, AXL and Akt mRNA then decreases, and there is also dose-dependant
Property, dosage is higher, the more notable (P of difference<0.01).(see Fig. 3)
The influence that 2.4 ART are expressed adenocarcinoma of lung PC9 cell EGFR, IGF1R, AXL and Akt albumen and apoptosis-related protein
2.4.1 ART can lower the phosphorylation level of PC9 cells AXL and Akt
Experimental group (ART 25 μm of ol/L and 100 μm of ol/L) and control group (0.1%DMSO solution) effect 48h are collected respectively
PC9 cells afterwards, extract after total protein with Western blot detect GAP-associated protein GAP EGFR, p-EGFR, IGF1R, p-IGFIR,
The change of AXL, p-AXL, Akt, p-Akt expression.It can be seen that intracellular EGFR, p-EGFR expression quantity of PC9 is more right after ART effects 48h
Unobvious according to group change, the expression quantity of IGF1R, p-IGF1R, AXL, p-AXL, Akt, p-Akt albumen has difference compared with control group
The reduction of degree, and become apparent with the expression reduction of phosphorylation level.(see Fig. 4)
2.3.2 expression of the ART to PC9 cell death related proteins has an impact
ART25 μm of ol/L and 100 μm of ol/L of collection is acted on 48 hours and the cell of 0.1%DMSO control groups is carried out respectively
The expression of Western blot quantitative determination apoptosis-related proteins.It was found that ART acts on Caspase-3, Active after 48h
The expression of caspase-3, PARP, Cleaved PARP has different degrees of rise.(see Fig. 5)
Experimental example 2:
Artesunate reverses the experiment in vitro of PC9/ER cell Tarceva resistances
1 materials and methods
1.1 major experimental materials
1.1.1 main agents
LY294002 is configured to 20nmol/L mother liquors (being dissolved with DMSO) first, is preserved for a long time in -20 DEG C of refrigerators, working solution
Empirically it is required with fresh cell culture fluid with preceding being prepared.
1.2 experimental techniques
1.2.1 cell recovery, the experimental technique cultivated, pass on and freeze are the same.
1.2.2 the influence using cck8 kits detection ART to PC9/ER ability of cell proliferation.
By the PC9 cells and PC9/ER cells of exponential phase with every hole 5 × 103The density of individual cell, is inoculated in 96 holes
Plate, per the μ l of hole 100, is placed in 37 DEG C, 5%CO2After cultivating 24h in incubator, ART is added its final concentration is respectively 6.25 μ
Mol/L, 12.5 μm of ol/L, 25 μm of ol/L, 50 μm of ol/L, 100 μm of μ l of ol/L volumes 150, are detected with cck8 methods.
1.2.3 Western blot detect the table of intracellular EGFR, IGF1R, AXL and Akt albumen and apoptosis-related protein
Up to situation of change
Collect respectively through the mono- medicine groups of ART (10 μm of ol/L), the mono- medicine groups of ER (5 μm of ol/L), ART joint ER groups, LY294002
PC9 cells and PC9/ER cells in exponential phase in positive controls, negative control group, using Western Blot realities
Test detection ART and combine ER medications to PC9 cells and PC9/ER cell EGFR, IGF1R, AXL and Akt albumen and apoptosis-related protein
Influence.
1.3 statistical analysis:
Every group of experiment in triplicate, statistical analysis is carried out with SPSS20.0 statistical softwares to obtained experimental data, is owned
Data are represented with mean ± standard deviation (mean ± SD), using one-way analysis of variance analysis group difference.P<0.05 thinks
It is variant, P<0.01 thinks there is significant difference.
2 results
2.1 influence using cck-8 methods detection ART to PC9 cells and PC9/ER ability of cell proliferation
Distinguished with the ART of final concentration of 6.25 μm of ol/L, 12.5 μm of ol/L, 25 μm of ol/L, 50 μm of ol/L and 100 μm of ol/L
PC9 cells and PC9/ER cells are acted on, the OD values of 490nm wavelength are determined after 48h, as a result shown, ART pairs of various concentrations
The multiplication capacity of PC9 cells and PC9/ER cells has an impact, and has dose dependent, and drug concentration is higher, and inhibiting rate is higher,
Wherein PC9 cells are 28.80 ± 2.84 μm of ol/L to the IC50 of ART, and PC9/ER cells are 25.78 ± 5.03 μ to the IC50 of ART
Mol/L, difference is not statistically significant.(see Fig. 6 and Biao 3)
IC50 the and IC10 values of the PC9 cells of table 3 and PC9/ER cells to Artesunate
2.2 ART and influence of the ER Combination interventions to adenocarcinoma of lung PC9/ER ability of cell proliferation
PC9/ER cells are respectively acting on ER Combination interventions with the mono- medicines of ER and ART, the OD of 490nm wavelength is determined after 48h
Value, and calculate IC50.Result shows that PC9/ER cells are 4.363 μm of ol/L to the IC50 of the mono- medicines of ER, and PC9/ER cells are to ART
It is 2.488 μm of ol/L with the IC50 of ER Combination interventions.(being shown in Table 4)
The PC9/ER cells of table 4 are to the mono- medicines of ER and the IC50 values of ART and ER Combination interventions
Reversing drug resistance multiple IC50 (ER)/IC50 (ER+ART)=1.75
2.3 ART and influence of the ER Combination interventions to adenocarcinoma of lung PC9/ER cell IGF1R and AXL protein expression situations
2.3.1 ART can lower the protein expression and phosphorylation level of PC9/ER cells IGF1R and AXL with ER drug combinations
Situation.
The mono- medicine groups of ART, the mono- medicine groups of ER, ART joint ER intervention groups are collected respectively acts on 48 hours and 0.1%DMSO control groups
PC9/ER cells, extract total protein after with Western blot detect IGF1R, p-IGF1R, AXL, p-AXL expression.
It can be seen that ART joint ER intervention groups IGF1R, p-IGF1R, the expression of AXL, p-AXL albumen have different degrees of drop compared with control group
It is low, and Expression of phosphorylated level reduction become apparent from.(see Fig. 7)
2.3.2 ART can lower the protein expression and phosphorylation level situation of PC9/ER cells Akt with ER Combination interventions.
The mono- medicine groups of ER, the mono- medicine groups of ART, ART joint ER intervention groups, ER is collected respectively to combine LY294002 (10 μm of ol/L) and do
Pre- group, ER+ART and LY294002 intervention groups act on the PC9/ER cells of 48 hours and 0.1%DMSO control groups, extract total protein
The expression of Akt and p-Akt is detected with Western blot afterwards.It can be seen that the mono- medicine groups of ART, ER joint ART medication group p-Akt eggs
White expression has different degrees of reduction compared with control group, compares with PI3K inhibitor LY294002 drug combination groups without substantially poor
It is different.(see Fig. 8)
2.3 ART and influence of the ER Combination interventions to adenocarcinoma of lung PC9/ER cell death related protein expressions
The mono- medicine groups of ER, the mono- medicine groups of ART, ART joint ER intervention groups are collected respectively acts on 48 hours and 0.1%DMSO control groups
PC9/ER cells, extract after total protein with Western blot detect Caspase-3, Active caspase-3, PARP,
The expression of Cleaved PARP.Thus it is clear that ART joints ER intervention groups Caspase-3, Active caspase-3, PARP,
The expression of Cleaved PARP albumen has different degrees of rise compared with control group, and Expression of phosphorylated level is raised and become apparent from.
(see Fig. 9)
Experimental example 3
Artesunate reverses the experiment in vivo of PC9/ER cell Tarceva resistances
1 experimental technique
The foundation of 1.1 experimental animal tumor models
The PC9/ER cell numbers bottle of exponential phase is selected, then with the 0.25% trypsase 1- containing 0.025%EDTA
2ml vitellophags, in being observed under inverted microscope, the new of 10%FBS are contained when cell withdraws projection change bowlder and is rapidly added on a small quantity
Fresh nutrient solution, softly blows and beats the cell for having digested and disengages it from cultivating bottle wall repeatedly, and is dispersed into cell suspension, then by cell
It is transferred in new centrifuge tube, in (1000rpm, 5min) is centrifuged on centrifuge, by the white cell precipitation PBS solution of gained
Cleaning 2-3 times, is counted with cell counting count board, and cell concentration then is adjusted into 1 × 10 with fresh medium (being free of FBS)7/
Ml, is aseptically immediately sent to SPF grades of animal feeding room.In the right side armpit hypodermic injection 1 × 10 of every nude mice7/ml
PC9/ER cells, there is obvious skin mound, as inject successfully in every injection 0.1ml, observable injection site, extraction rapidly
Syringe needle, skin of sterilizing.Continuous Observation has 48 nude mices (52 nude mices, dead 4 altogether) rice occur at the armpit of right side after 1 week
The big lesser tubercle of grain, illustrates that model in nude mice is successfully established.Continue to cultivate and observe.
1.2 experiment packets
48 nude mices are randomly divided into 6 groups, every group 8.
Experiment packet is:Negative control group
The mono- medicine groups of ART
The mono- medicine groups of ER
ER+ART Combination intervention groups
ER+LY294002 Combination intervention groups
ER+ART+LY294002 intervention groups
1.3 medications
Treat that tumor average diameter reaches 100mm3After start gavage treatment, once a day, saline control group give 0.5ml without
Bacterium physiological saline gavage.
1.4 antitumor actions are observed
Observe nude mice once within every 2 days after administration, main contents observe tumour to weigh nude mice body weight and measurement gross tumor volume
The major diameter (Length) and minor axis (width) of measurement knurl body are needed during volume, gross tumor volume (v), v=(length is finally calculated
×width)/2.14d after medication, wherein 5 tumor bearing nude mices are put to death with cervical dislocation method, are weighed, relatively more each experimental group nude mice
The situation of change of body weight.Then knurl body is completely stripped, observation knurl body color, shape, coating and surrounding wetting situation.Every group remains
Remaining nude mice continues to observe to natural death, has indifference to observe its Overall survival.
1.5 immunofluorescences
1st, frozen section is fixed:Frozen section takes out rewarming from refrigerator, dries moisture, and cold acetone fixes 10min, treats third
Ketone it is completely dry after rocked on decolorization swinging table in PBS (PH7.4) washing 3 times, each 5min.
2nd, antigen retrieval:Histotomy is placed in the reparation box for filling with EDTA antigen retrievals buffer solution (PH8.0) in microwave
Antigen retrieval is carried out in stove.Low fiery 10min, should prevent buffer solution excessive vaporization during this, be sure not dry plate.Will after natural cooling
Slide is placed in PBS (PH7.4) and washing 3 times, each 5min is rocked on decolorization swinging table.(liquid and Repair strength are repaired according to group
Knit to determine)
3rd, BSA closings:Section is drawn a circle (prevent antibody from flowing away) with groupization pen after slightly drying around tissue, is added dropwise in circle
With 3%BSA uniform fold tissues, room temperature closing 30min.
4th, primary antibody is added:Confining liquid is gently got rid of, the primary antibody that PBS is prepared by a certain percentage is added dropwise in section, section keeps flat
In 4 DEG C of overnight incubations in wet box.(wet box is interior plus a small amount of water prevents antibody from evaporating)
5th, secondary antibody is added:Slide is placed in PBS (PH7.4) and washing 3 times, each 5min is rocked on decolorization swinging table.Section is slightly
The secondary antibody that kind corresponding to primary antibody is added dropwise after drying in circle covers tissue, lucifuge incubation at room temperature 50min.
6th, DAPI redyes nucleus:Slide is placed in PBS (PH7.4) and washing 3 times is rocked on decolorization swinging table, every time
5min.Section is added dropwise DAPI dye liquors, lucifuge incubation at room temperature 10min in circle after slightly drying.
7th, mounting:Slide is placed in PBS (PH7.4) and washing 3 times, each 5min is rocked on decolorization swinging table.Section is slightly got rid of
With anti-fluorescent quenching mountant mounting after dry.
8th, microscopy is taken pictures:Cut into slices in being observed under Nikon inverted fluorescence microscope and gather image.(burst of ultraviolel wavelength 330-
380nm, launch wavelength 420nm;FITC green glows excitation wavelength 465-495nm, launch wavelength 515-555nm;CY3 feux rouges excitation waves
510-560 long, launch wavelength 590nm)
9th, result interpretation:It is blueness under ultraviolet exciting that DAPI dyes the nucleus for coming, and positive expression is corresponding fluorescence
The feux rouges or green glow of element mark
1.6 statistical analysis
Every group of experiment in triplicate, statistical analysis is carried out with SPSS20.0 statistical softwares to obtained experimental data, is owned
Data are represented with mean ± standard deviation (mean ± SD), using one-way analysis of variance analysis group difference.P<0.05 thinks
It is variant, P<0.01 thinks there is significant difference.
2 results
Nude mice in the experiment of 2.1 nude mice lotus knurls and into knurl position
PC9/ER cells are inoculated with nude mice by subcutaneous, about 1 week after inoculation, the big brief summary of millet appearance can be touched right side armpit is subcutaneous
Section, gradually increases later, and transplanting success rate is 98% (47/48).
2.2 nude mice changes of weight
After each experimental group inoculation PC9/ER cells 7d, the Tumor formation of tumor bearing nude mice is observed, tumor average diameter to be measured reaches
100mm3After start gavage treatment.Once a day, body weight of every 2 days of period weighing, counts each group nude mice after Continuous Observation 14d
Body weight, as a result show, very much not, toxicity is not significantly increased each group nude mice body weight amplitude of variation after showing drug combination.(see
Figure 10)
2.3 tumor volumes change
After model of nude mice bearing tumor is successfully established, tumor average diameter to be measured reaches 100mm3After start gavage treatment.Daily
Once, tumor volume of every 2 days of period measurement, unifies to put to death nude mice with cervical dislocation after medication 14d, peels off knurl body, system
The tumor volume of measurement in meter 14d, tumorous size has differences in finding different experiments group, and each experimental group tumor volume is more right
Reduced according to group.(see Figure 11)
Knurl body tissue in the experiment of 2.4 nude mice lotus knurls
Each experimental group in unifying to put to death nude mice with cervical dislocation after gavage treatment 14d, then completely strips knurl body,
Tumorous size is different during each experimental group can be observed, and the knurl body of the visible tumor bearing nude mice of naked eyes is in nodositas, and coating is mostly more complete,
Being in canescence not to surrounding wetting, knurl body, without the performance such as hemorrhagic necrosis stove more.
The protein expression of Akt and p-Akt in 2.5 Immunofluorescence test nude mice knurl body tissues
After model of nude mice bearing tumor is successfully established, tumor average diameter to be measured reaches 100mm3After start gavage treatment.Daily
Once, unify to put to death nude mice with cervical dislocation after medication 14d, peel off knurl body, -80 DEG C of refrigerator frosts are immediately placed in, using ice
Freeze the protein expression of Akt and p-Akt in the Immunofluorescence test nude mouse tissue of section, as a result show the mono- medicines of ART and drug combination
The protein expression of the internal Akt and p-Akt of group is relative to be lowered.
Discuss
Non-small cell lung cancer (NSCLC) is most common Lung Cancer Types, accounts for 80% or so of all lung cancer, although Synthetic
(operation, chemotherapy and radiation) is treated to have been developed, but 5 years survival rates of Patients with Non-small-cell Lung are only left 17%
It is right[22].Current clinical research shows that EGF-R ELISA (EGFR) tyrosine kinase inhibitor (TKI) is replaced as Ji is non-
Buddhist nun and Tarceva can significantly improve the Overall survival of EGFR genetic mutation (such as 19 exons mutations) cancer patient.However,
Most of tumours can all produce EGFR-TKI resistances after (median time 8-12 month) after a while, and EGFR-TKIs is obtained
Property resistance is typically inevitable, which has limited its clinical practice.However, the mechanism of EGFR-TKIs acquired resistances is not yet
It is fully apparent from.
The influence topmost reason of molecular targeted therapy clinical practice is acquired resistance, causes EGFR-TKI acquired resistance to
The mechanism of medicine has a lot, in addition to EGFR mutation and MET proto-oncogenes are expanded, it is also recently found that the machine of other acquired resistances
System, such as the activation of by-passing signal (such as c-Met, HGF, AXL)[23], downstream signal exception (as K-RAS mutation, PTEN
Missing), the apoptotic pathways (such as BCL2-like11/BIM polymorphisms missing) of EGFR-TKI mediations and histology change.
Therefore we should actively find and develop that Synergistic action is strong, toxic and side effect is small, can reverse small molecule targeted therapy resistance
Medicine, is the direction of domestic and foreign scholars research
Research in recent years finds that effective anti-knurl composition is extracted and found from Chinese herbal medicine has turned into the uncommon of oncotherapy
Hope and new way.Wherein artemisinin-based drug is the focus of research, has many researchs to antineoplastic point of Artesunate therein
Handset system is inquired into, and current research has proven to Artesunate and PI3K/Akt, NF- κ B, MAPK, PKC, STATs etc. are believed
Number path has inhibitory action, but specific mechanism is unclear.The result of study of this seminar early stage shows Artesunate energy
Suppress growth and the propagation of human pulmonary epithelial cells with concentration and time dependence, and can dose-dependently induce thin
Born of the same parents' apoptosis.
Based on background above, we are further inquired into the antitumor mechanism of ART, are detected using cck-8 first
ART treatment human lung adenocarcinoma PC9 cell 24h, 48h, 72h of various concentrations, as a result find ART equally can with concentration and time according to
Property ground is relied to suppress PC9 cell growths and propagation, this shows that ART has CDCC to adenocarcinoma of lung, and it is thin that it can slow down tumour
The propagation of born of the same parents.And the result of qRT-PCR and Western Blot finds, after being processed through ART, intracellular IGF1R, AXL and Akt
MRNA and protein level have different degrees of downward, while the protein expression of its activated form p-IGF1R, p-AXL and p-Akt
Downward becomes apparent from.And intracellular apoptosis-related protein Caspase-3, Active caspase-3, PARP, Cleaved PARP is equal
In the presence of different degrees of rise, wherein Active caspase-3 and Cleaved PARP raise more obvious.These result tables
Influences of the bright ART to PC9 ability of cell proliferation may be by suppressing EGFR by-passing signals (IGF1R, AXL) and downstream signal is logical
The activation on road (PI3K/Akt) realizes, may be relevant with the apoptosis of further induction PC9 cells.
The activation of by-passing signal is to cause one of important mechanisms of secondary resistance.The research display transmembrane protein of the past
IGF1R can bypass the action target spot of EGFR-TKI with the PI3K/Akt signal paths in alternative activation downstream, reach cell and continue
Propagation and the effect of anti-apoptotic, cause EGFR-TKI to fail to respond to any medical treatment, so as to produce acquired resistance[24-25].Also research shows
AXL plays an important role in the cellular activities such as cell propagation, migration, diffusion, anti-apoptotic, EMT[26], and under AXL
Trip molecule has a lot, including PLC γ, MMP-9, SOCS, PI3K/Akt, ERK1/2, SRC etc.[27-28].Sawu etc. is in stomach cancer MKN7
Found in cell line, Gas6/AXL signal pathways can start downstream PI3K/Akt signal paths, prevent cell startup program
Death program, suppresses apoptosis in gastric cancer[29-30].By-passing signal IGF1R and AXL common downstream signaling pathway is PI3K/Akt
Signal path, the signal path is the important path of cell survival, and the Akt of activation activates or suppress downstream by phosphorylation
Target protein Bad, Caspase 9, IKK, mTOR and p21Clip etc., and then adjust propagation, differentiation, apoptosis and the migration of cell.
Akt as PI3K/Akt signal paths hinge, the overexpression in kinds of tumors, prognosis with tumour is into negative correlation.P-Akt makees
It is the activated form of Akt, the propagation of cell can be promoted, suppresses the apoptosis of cell, and then promote transfer, the angiogenesis of tumour.
Its unique biological function determines its important function in tumour[31].Research also shows PI3K/Akt signal paths
Overactivity can cause EGFR-TKI resistances, and suppressing PI3K/Akt signal paths can make cell line regain medicaments insensitive
Property[32]。
Therefore, it is presumed that, Artesunate can be by suppressing EGFR by-passing signals IGF1R, AXL and downstream signaling pathway
The activation of PI3K/Akt makes acquired resistance cell again sensitive to molecular targeted agents.In order to verify our supposition, we
By building PC9/ER resistant models, there is the situation of acquired resistance in simulation clinic EGFR-TKIs, carry out improving grinding for resistance
Study carefully.
We pass through heavy dose of Tarceva constant impingement PC9 cells first, obtain the resistance to Tarceva of Secondary cases thin
Born of the same parents system PC9/ER cells, drug resistance is detected with cck-8, and resistance multiple is 11.94 times, points out to be successfully established resistance to Tarceva
PC9/ER cells.Then by Real-time RT-PCR and Western Blot find PC9/ER cells in exist IGF1R,
The overexpression of AXL and Akt, as a result points out the acquired resistance of PC9 cells with the activation of EGFR by-passing signals (such as IGF1R, AXL)
It is relevant, it is consistent with current result of study.
Then we further study pharmacological actions of the ART to PC9/ER cells, and the result display ART of cck-8 can be same
The propagation of PC9/ER cells, and IC50 and PC9 cell no significant differences can be suppressed, it is resistance in the absence of intersecting between prompting ART and ER
The property of medicine.Next we have detected the inhibitory action of the mono- medicines of ER and joint ART and ER to PC9/ER cells, hair with cck-8 methods again
PC9/ER cells IC50 is lower after existing Combination intervention, illustrates there is reversing drug resistance by drug combination that (reversal index is 1.75
Times), also illustrate that Artesunate can make PC9/ER cells recover the sensitiveness to ER again.And the result table of Western Blot
Bright PC9/ER intracellular IGF1R, AXL and Akt protein level has different degrees of downward, especially shows its phosphorylation water
On flat, wherein Combination intervention group is lowered more obvious.And apoptosis-related protein Caspase-3, Active caspase-3,
PARP, Cleaved PARP have different degrees of rise.In testing in vivo, it has been found that the mono- medicines of ART and drug combination
The protein expression of group internal IGF1R, AXL and Akt is lowered, but drug combination does not increase its toxic and side effect.These
Result shows that ART can suppress the propagation of PC9/ER cells really, and perhaps the mono- medicines of ART and ART and ER drug combinations can play
Improve resistance, PC9/ER cell lines is regained the pharmacological action of drug susceptibility.Its mechanism may make by suppressing EGFR
The activation of by-passing signal (IGF1R, AXL) and downstream signaling pathway (PI3K/Akt) and the apoptosis of induction PC9/ER cells are realized
's.
In sum, the study find that, IGF1R, AXL and its downstream signaling pathway (PI3K/Akt) take part in NSCLC's
Generation evolution, and ART can be by suppressing the activation and rise of IGF1R, AXL and its downstream signaling pathway (PI3K/Akt)
Apoptosis-related protein plays antineoplastic action, and it is logical also to suppress IGF1R, AXL and its downstream signal in mdr cell
The activation on road (PI3K/Akt) and apoptosis-induced, the Suppressive effect of enhancing Tarceva, make the cell of resistance to Tarceva again to strategic point
Lip river is sensitive for Buddhist nun.This research provides new foundation for Artesunate as candidate anti-tumor medicine, improves patients with lung cancer prognosis
One new thinking is provided and brings new hope to patients with lung cancer.
Full text conclusion
1.ART can suppress the propagation of human lung adenocarcinoma PC9 cells, and its mechanism may be believed with inducing cell apoptosis and suppression EGFR
The activation of number path is relevant.
2.ART can reverse the resistance of PC9/ER, its mechanism be probably with suppress EGFR by-passing signals paths (IGF1R,
AXL the activation) with downstream signaling pathway (PI3K/Akt) is relevant.
Claims (2)
1. a kind of new opplication of Artesunate, it is characterised in that:The Artesunate is used to reverse adenocarcinoma of lung Tarceva resistance.
2. the new opplication of Artesunate according to claim 1, it is characterised in that:Artesunate and Tarceva joint are used
Medicine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611106935.3A CN106727586A (en) | 2016-12-06 | 2016-12-06 | A kind of new opplication of Artesunate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611106935.3A CN106727586A (en) | 2016-12-06 | 2016-12-06 | A kind of new opplication of Artesunate |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106727586A true CN106727586A (en) | 2017-05-31 |
Family
ID=58878160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611106935.3A Pending CN106727586A (en) | 2016-12-06 | 2016-12-06 | A kind of new opplication of Artesunate |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106727586A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106668866A (en) * | 2017-02-13 | 2017-05-17 | 江苏省中医药研究院 | Medicinal composition for resisting non-small cell lung cancer, and application thereof |
CN109432086A (en) * | 2018-12-05 | 2019-03-08 | 江苏省中医药研究院 | The application of qinghaosu or derivatives thereof and the composition of EGFR-TKI targeted drug |
CN113004301A (en) * | 2021-03-11 | 2021-06-22 | 广西师范大学 | Artesunate-based-diphenylurea derivative ARS-DPU as well as preparation method and application thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060084675A1 (en) * | 2004-10-18 | 2006-04-20 | Thomas Efferth | Combined treatment with artesunate and an epidermal growth factor receptor kinase inhibitor |
CN101125142A (en) * | 2007-07-24 | 2008-02-20 | 北京中医药大学东直门医院 | Application of artemisine in preparing artitumor multi-medicine-resistant medicine |
CN104940203A (en) * | 2015-06-26 | 2015-09-30 | 南通大学附属医院 | Medicine composition for lung cancer |
US9314460B1 (en) * | 2013-04-09 | 2016-04-19 | Stc.Unm | Method for cancer cell reprogramming |
CN106591308A (en) * | 2016-12-06 | 2017-04-26 | 遵义医学院附属医院 | Human pulmonary carcinoma erlotinib drug tolerance improving shRNA |
CN106668866A (en) * | 2017-02-13 | 2017-05-17 | 江苏省中医药研究院 | Medicinal composition for resisting non-small cell lung cancer, and application thereof |
CN109432086A (en) * | 2018-12-05 | 2019-03-08 | 江苏省中医药研究院 | The application of qinghaosu or derivatives thereof and the composition of EGFR-TKI targeted drug |
-
2016
- 2016-12-06 CN CN201611106935.3A patent/CN106727586A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060084675A1 (en) * | 2004-10-18 | 2006-04-20 | Thomas Efferth | Combined treatment with artesunate and an epidermal growth factor receptor kinase inhibitor |
CN101125142A (en) * | 2007-07-24 | 2008-02-20 | 北京中医药大学东直门医院 | Application of artemisine in preparing artitumor multi-medicine-resistant medicine |
US9314460B1 (en) * | 2013-04-09 | 2016-04-19 | Stc.Unm | Method for cancer cell reprogramming |
CN104940203A (en) * | 2015-06-26 | 2015-09-30 | 南通大学附属医院 | Medicine composition for lung cancer |
CN106591308A (en) * | 2016-12-06 | 2017-04-26 | 遵义医学院附属医院 | Human pulmonary carcinoma erlotinib drug tolerance improving shRNA |
CN106668866A (en) * | 2017-02-13 | 2017-05-17 | 江苏省中医药研究院 | Medicinal composition for resisting non-small cell lung cancer, and application thereof |
CN109432086A (en) * | 2018-12-05 | 2019-03-08 | 江苏省中医药研究院 | The application of qinghaosu or derivatives thereof and the composition of EGFR-TKI targeted drug |
Non-Patent Citations (2)
Title |
---|
周建国,等: "抑制Rab25基因表达的人NSCLC厄洛替尼耐药细胞PC9/ER的建立", 《中华肿瘤防治杂志》 * |
马虎: "青蒿琥酯对NSCLC抗瘤及增强厄洛替尼体内外抗瘤活性的实验研究", 《中国博士学位论文全文数据库 医药卫生科技辑》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106668866A (en) * | 2017-02-13 | 2017-05-17 | 江苏省中医药研究院 | Medicinal composition for resisting non-small cell lung cancer, and application thereof |
CN109432086A (en) * | 2018-12-05 | 2019-03-08 | 江苏省中医药研究院 | The application of qinghaosu or derivatives thereof and the composition of EGFR-TKI targeted drug |
CN113004301A (en) * | 2021-03-11 | 2021-06-22 | 广西师范大学 | Artesunate-based-diphenylurea derivative ARS-DPU as well as preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chen et al. | Lycium barbarum polysaccharide protects against LPS-induced ARDS by inhibiting apoptosis, oxidative stress, and inflammation in pulmonary endothelial cells | |
Hsiao et al. | The decline of autophagy contributes to proximal tubular dysfunction during sepsis | |
CN102427814A (en) | Kinase protein binding inhibitors | |
CN106727586A (en) | A kind of new opplication of Artesunate | |
Xiao et al. | Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation | |
CN109568299A (en) | Ambroxol purposes in preparing tumor chemotherapeutic drug Synergistic preparations | |
CN104188949B (en) | Purposes of the chlorogenic acid in the medicine for preparing treatment mesoglioma | |
CN107669676A (en) | A kind of application of quinoline of N isosteres iridin in medicines resistant to liver cancer | |
CN106727500A (en) | The application of dihydroartemisinine, suppression medicine and its application | |
CN109125329A (en) | The new application of 1 class Niemann-Pick protein inhibitor of c-type | |
CN109602752B (en) | Triptolide is in induction cancer cell autophagy and hdac inhibitor is cooperateed with to treat the application in tumour | |
CN103969452A (en) | Classification diagnostic kit for liver cancer Sorafenib personalized treatment | |
CN104147127B (en) | A kind of Chinese medicine composition and its preparation method and application for treating malignant tumour | |
CN106955292B (en) | A kind of pharmaceutical composition and purposes for treating the cancer of the esophagus | |
Gong et al. | Hyperthermic intraperitoneal chemotherapy with recombinant mutant human TNF-α and raltitrexed in mice with colorectal-peritoneal carcinomatosis | |
CN109371130A (en) | RIPOR3 is in preparation for the application in the biological products of breast cancer detection and treatment | |
CN104083368A (en) | Application of G-1 in preparation of G protein coupled receptor 30-based triple negative breast cancer targeting drugs | |
CN108704139A (en) | A kind for the treatment of of pancreatic cancer pharmaceutical composition with synergy | |
CN107144695A (en) | Application of the Arl13b albumen in cancer diagnosis | |
CN107459502A (en) | Flavone compound and its purposes in antineoplastic is prepared | |
CN102008715B (en) | Antitumor MA-TNF alpha medicine composition and application thereof | |
CN107441075A (en) | A kind of antineoplastic combination medicine and its purposes in cancer therapy drug is prepared | |
Ge et al. | Effect of Tumor Red Blood Cell Immunity and Tumor Cell Cycle in Mice Bearing Solid Liver Cancer with Intelligent Cancer Zhongning Therapeutic Apparatus | |
CN109223801A (en) | A kind of new the killing agent of gastric cancer tumor stem cell and its application | |
CN108379282A (en) | A kind of drug and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170531 |